MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment

2026-06-24 14:35:19 ET

The last time I spoke about MacroGenics, Inc. ( MGNX ) it was with a Seeking Alpha article entitled " Positive Safety Update Leads To Two Major Inflection Points In 2024 ." With respect to that article, the company was in the process of evaluating its antibody-drug conjugate [ADC] B7-H3 candidate vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC] in the ongoing phase 2 TAMARACK study. Things were looking good then after it cleared a safety hurdle for fewer discontinuations using 2 mg/kg and 2.7 mg/kg of vobra duo to treat these patients. As opposed to the prior phase 1 study, where 3 mg/kg saw high rates of treatment discontinuation....

Read the full article on Seeking Alpha

For further details see: